References
- Kessler IIf I, Haushofer AC. Molecular diagnostics in laboratory medicine. J. Clin. Viral 20,1–40 (2001).
- •• A comprehensive, exaustive and upgradedreview of current techniques of molecular diagnostics in laboratory medicine.
- Screiber GB, Bush MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl Med. 334,1685–1690 (1996).
- •• Analysis of factors and cofactors associatedwith the risk of transfusion-transmitted viral infections in blood banking and medical care.
- Ohno T, Lau JYN. The gold-standard, accuracy and the current concepts: hepatitis C virus genotype and viremia. Hepatology 24,1312–1315 (1996).
- Pawlotsky JM, Roudot-Thoraval F, Bastie A et al Factors affecting treatment responses to interferon-alpha in chronic hepatitis Can. Infect. Dis. 174,1–7 (1996).
- Pawlotsky JM. Measuring hepatitis C viremia in clinical samples: can we trust the assays? Hepatology26,1–4 (1997).
- Flichman D, Colombatto P, Randone A et al Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study. Clin. Diag. Viral 8,63–70 (1997).
- Damen M, Zaaijer HJ, Reesink H etal. International collaborative study on the 2nd Eurohep HCV-RNA reference panel, Viral. Meth. 58,116-120 (1996).
- •• A paradigmatic and sophisticated exampleof a quality control analysis of currently available NAAT for HCV-RNA.
- Saldanha J. Validation and standardization of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J. Clin. Viral. 20,7–13 (2001).
- •• An expert opinion on facts, problems andpossible solutions for the validation and standardization of NAAT for the detection of blood borne infections.
- Courouc6 AM, Le Marrec N, Bouchardeu F etal. Efficacy of HCV core antigen detection during pre-seroconversion period. Transfusion 40,1198-1202 (2000). A well performed and extensive study of the sensitivity, specificity and reproducibility of a HCcAg assay as compared to HCV-RNA NAAT.
- NIH Consensus Development Conference. Management of hepatitis C. Hepatology26, 83–108 (1997).
- •• The current standard of care for therapy ofchronic hepatitis C in USA.
- AISF Committee for Antiviral Therapy: guidelines for the treatment of chronic viral hepatitis. Ital. .1. Castroenterol Hepatol 29, 583–596 (1997).
- Davis GL, Esteban-Mur R, Rustgi V etal. Interferon a-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl Med. 339(21), 1493–1499 (1998).
- Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology33, 419–423 (2001).
- Zeuzem S, Schmidt JM, Lee J-H, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivz effects of ribavirin and interferon alfa on viral turnover. Hepatology 28,245–252 (1998).
- •• An elegant application of viral dynamics tothe understanding of the mechanism of response to interferon-ribavirin combination therapy in chronic hepatitis C patients.
- Neumann AU, Lam NP, Dahari H eta]. Hepatitis vrial dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282,103–107 (1998).
- •• The pioneer work on the first model ofHCV dynamics in patients who respond to interferon therapy.
- Hermann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antiviral Ther. 5,85–90 (2000).
- Colombatto P, Baldi M, Oliveri F, Randone A, Bonino F, Brunetto MR. Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype lb infected patients: a pilot study. Dig. Liver Dis. 32, 211–216 (2000).
- Colombatto P, Civitano L, Oliveri F eta]. Dynamics of HCV and ALT during a-interferon therapy. 8th International Meeting on HCV ancl Related Viruses (2–5 September 2001), Paris, France, Abstract Book.
- •• New progress in modeling the dynamics ofbiochemical and virologic response during different types of response to interferon therapy using quantification of both ALT and HCV-RNA.
- Colloredo Mels G, Bellati G, Leandro G etal Quantitative analysis of IgM antiHBc in chronic hepatitis B patients using a new 'grey-zone' for the evaluation of 'borderline'values. Hiputol. 25,644–648 (1996).
- • An example of validation and standardization of an assay for the quantification of IgM antiHBc in patients with chronic hepatitis B.